New article published: Cotte et al. 2024

Congratulations to Prof. Cotte and colleagues on the publication of the recommendations of French learned societies on the management of rectal cancer in the journal Digestive and Liver Disease. We are delighted to have contributed to the success of this article!

𝐑𝐞𝐜𝐭𝐚𝐥 𝐚𝐝𝐞𝐧𝐨𝐜𝐚𝐫𝐜𝐢𝐧𝐨𝐦𝐚 accounts for the largest proportion of rectal cancers, representing around 14,000 new cases per year. It is the 𝐭𝐡𝐢𝐫𝐝 𝐦𝐨𝐬𝐭 𝐜𝐨𝐦𝐦𝐨𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 in men and the second in women. Risk factors include age, a diet rich in animal fats, inactivity, being overweight, as well as alcohol and tobacco consumption. 𝐒𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐟𝐨𝐫 𝐭𝐡𝐢𝐬 𝐜𝐚𝐧𝐜𝐞𝐫 is carried out every two years between the ages of 50 and 74, enabling it to be detected early and potentially treated.

This article presents the 𝐫𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐚𝐭𝐢𝐨𝐧𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐅𝐫𝐞𝐧𝐜𝐡 𝐈𝐧𝐭𝐞𝐫𝐠𝐫𝐨𝐮𝐩 on the diagnosis, treatment and management of 𝐫𝐞𝐜𝐭𝐚𝐥 𝐚𝐝𝐞𝐧𝐨𝐜𝐚𝐫𝐜𝐢𝐧𝐨𝐦𝐚. The French medical and surgical learned societies involved in the treatment of this disease have 𝐠𝐫𝐚𝐝𝐞𝐝 𝐭𝐡𝐞 𝐫𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐚𝐭𝐢𝐨𝐧𝐬 𝐟𝐫𝐨𝐦 𝐀 𝐭𝐨 𝐂. The treatment of adenocarcinoma has been divided into four groups 𝐚𝐜𝐜𝐨𝐫𝐝𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐬𝐭𝐚𝐠𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐜𝐚𝐧𝐜𝐞𝐫: T1N0, T2N0, T12N+ or T3+ all N and T3N2 or T+ all N, with different treatment recommendations. These recommendations aim to provide 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐚𝐧𝐝 𝐜𝐨𝐧𝐬𝐭𝐚𝐧𝐭𝐥𝐲 𝐨𝐩𝐭𝐢𝐦𝐢𝐳𝐞𝐝 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬.

It should also be noted that a small clinical trial recently demonstrated the 𝐝𝐢𝐬𝐚𝐩𝐩𝐞𝐚𝐫𝐚𝐧𝐜𝐞 𝐨𝐟 𝐚 𝐩𝐚𝐫𝐭𝐢𝐜𝐮𝐥𝐚𝐫 𝐭𝐲𝐩𝐞 𝐨𝐟 𝐫𝐞𝐜𝐭𝐚𝐥 𝐜𝐚𝐧𝐜𝐞𝐫 𝐢𝐧 𝟏𝟎𝟎% of its patients in the United States. This clinical trial, called Jemperli, is testing the effect of an immunotherapy (dostarlimab) on 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐭𝐮𝐦𝐨𝐫𝐬 (mismatch repair deficiency or microsatellite instability).